Of course, these also need to be cross-referenced for relevance in the human disease, but have demonstrable potential to open up new therapeutic avenues; for example, where profiling of mouse tumours highlighted the druggable target Met as a secondary mutation in p53-deficient tumours, pointing to a putative new target for treating triple-negative breast cancer (Francis et al., 2015; Pfefferle et al., 2016). Here, TP53 is linked to neoplasm.